Overview

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the safety, tolerability and dose-limiting toxicities of KW-2478 and to determine the Maximum Tolerated Dose and recommended Phase II dose for patients with relapsed/refractory MM, CLL or B-cell NHL.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin UK, Ltd.